product summary
Loading...
company name :
OriGene
product type :
antibody
product name :
IL12B Mouse Monoclonal Antibody [Clone ID: B-P24]
catalog :
TA352740
quantity :
500 µg
price :
574 USD
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
B-P24
reactivity :
human
more info or order :
product information
SKU :
TA352740
Category :
Antibodies
Sub-Category :
Primary Antibodies
Name :
IL12B Mouse Monoclonal Antibody [Clone ID: B-P24]
Description :
Mouse Monoclonal Anti-IL-12/23p40 Antibody
Size :
500 µg
Price US :
574 USD
Delivery Time US :
3 Weeks
Symbol :
IL12B
Uniprot ID :
P29460
Accn :
NM_002187
Clonality :
Monoclonal
Clone Name :
B-P24
Host :
Mouse
Isotype :
IgG1
Reactivity :
Human
more info or order :
company information

OriGene
9620 Medical Center Dr., Suite 200
Rockville, MD 20850
Rockville, MD 20850
custsupport@origene.com
https://www.origene.com1-888-267-4436
headquarters: USA
OriGene Technologies, Inc. is a gene centric life sciences company dedicated to support biomedical scientists in gene functions and drug discovery. OriGene’s novel product line includes the world’s largest collections of cDNA clones (TrueClone and TrueORF), shRNA (HuSH-29), purified human recombinant proteins, high quality TrueMAB™ monoclonal antibodies to human proteins, 100,000 highly validated human tissues, and qPCR arrays. OriGene also provides a broad range of antibody validation products including genome-wide tagged antigen standards and extensive IHC slides derived from our tissue collection. OriGene is a Luminex Certified Partner™ and offers multiplexed immunoassays and multiplexed assays for a broad range of biomarkers.
related products
browse more products
- IL12B Mouse Monoclonal Antibody [Clone ID: AW-1] | TA352741
- IL12A Mouse Monoclonal Antibody [Clone ID: QS-12p70] | TA352742
- IL13 Mouse Monoclonal Antibody [Clone ID: B-B13] | TA352743
- IL23 (IL23A) Mouse Monoclonal Antibody [Clone ID: B-Z23] | TA352744
- TNF alpha (TNF) Mouse Monoclonal Antibody [Clone ID: B-F7] | TA352746
questions and comments